PMS46 TREATMENTS FOR UPPER-LIMB POST-STROKE SPASTICITY: A CRITICAL EVALUATION  by Olvey, EL et al.
PMS46
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OBJECTIVE: The purpose of this study was to conduct a critical
analysis of the current treatments for upper-limb post-stroke
spasticity. METHODS: Using search terms including spasticity,
stroke, hemiplegia, phenol, baclofen, tizanidine, dantrolene, ben-
zodiazepine, and botulinum toxin, the databases MEDLINE,
EMBASE, and Cochrane Controlled Trials Register were used to
identify studies in English published from 2004–December 2007.
Citations of the extracted articles were reviewed to identify
any further articles not captured through the database search.
Articles were excluded for the following reasons: lower extremity
treatments, pediatric studies, commentaries, duplicate studies,
and those that focused on the use of treatments for spasticity
secondary to a non-stroke etiology (e.g. multiple sclerosis, cere-
bral palsy, etc.). RESULTS: A total of 34 studies were reviewed
and assessed using the Oxford Levels of Evidence quality scale.
Fourteen clinical trials, two pooled analyses, two meta-analyses,
one cost-effectiveness study, two retrospective cohort studies,
three case reports/case-series, ﬁve systematic reviews, and
ﬁve non-systematic reviews were identiﬁed. Thirty-one studies
focused on botulinum toxin. All clinical trials compared botuli-
num toxin to either placebo or no treatment. Eleven studies
followed patients through one treatment cycle (generally, 12–16
weeks) to determine the duration of treatment efﬁcacy. Three
clinical trials completed multiple treatment cycles which lasted
24–42 weeks. Most clinical trials measured spasticity in multiple
locations of the arm, such as the ﬁngers, wrist and shoulder. All
studies used multiple outcome measures, including instruments
that assessed spasticity, pain, quality of life, disability, and func-
tional status. All clinical trials showed a signiﬁcant difference in
spasticity when botulinum toxin was used, as compared either to
baseline measurements or placebo. CONCLUSION: This analy-
sis showed that botulinum toxin effectively reduces upper-limb
spasticity in post-stroke patients. Despite utilization of broad
search criteria, no current trials demonstrating the efﬁcacy of
other treatments were identiﬁed.
RESPIRATORY-RELATED DISORDERS—
Clinical Outcomes Studies
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COMPARISON OFTHE EFFECTIVENESS OF ONEVERSUSTWO
ANTIBIOTICS INTHETREATMENT OF COMMUNITY
ACQUIRED PNEUMONIA (CAP).AN ANALISYS USING
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OBJECTIVE: To compare the effectiveness of one versus two
antibiotics in the treatment of community acquired pneumonia
(CAP), related to mortality, inpatient stay and clinical outcomes.
METHODS: Data from an observational study with CAP was
collected during 2005–2007 in Santiago-Chile (sample = 321).
One group was treated with one antibiotic (n = 115) and the
other with two antibiotics (n = 202). Both were followed during
their hospital stay, and clinical outcomes were collected. For each
individual, the propensity score was estimated, which is the a
priori probability of being assigned to receive treatment with
two antibiotics. This was performed with the use of logistic
regression, including signiﬁcant co-variables that occurred before
the actual treatment initiation. Analysis of confounder variables
was also developed, in order to compare with Propensity Score
approach. RESULTS: Univariate analysis showed signiﬁcant
positive association between two antibiotics and the progression
to septic shock (RR = 4.15), acute renal failure (RR = 2.04),
acute respiratory failure (RR = 3.02) and radiologic impairment
(RR = 5.10). Combined treatment was also associated with
lower probability to be discharged from hospital (HR = 0.56).
However, when the analysis was adjusted by Propensity Score,
these associations disappeared. No inversion of the association
was observed. Additionally, when treatment with two antibiotics
was adjusted by severity of the CAP (Fine Score), similar results
were observed with the exception of acute respiratory failure and
hospital stay. CONCLUSION: In adult patients with CAP, treat-
ment with two antibiotics versus one was not associated with
lower mortality, decreased inpatient stay or improved clinical
evolution. Analysis using Propensity Score was a useful method,
because it was able to explain all those associations observed in
the univariate analysis. (Supported by FONDECYT 1050734)
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DISEASE
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OBJECTIVE: The comparative efﬁcacy of commonly prescribed
drugs for the treatment of chronic obstructive pulmonary disease
(COPD) is under debate. Therefore, we conducted a mixed-
treatment comparison meta-analysis (MTC) to assess the efﬁcacy
and tolerability of these agents. METHODS: A systematic litera-
ture search through October 2007 was performed to identify
randomized controlled trials of long-acting beta-agonist (LABA),
tiotropium, inhaled corticosteroid (ICS), and/or combination ICS/
LABA therapy in patients with COPD. MTC methods were used
to combine direct, within-trial and between-drug comparisons
with indirect evidence from the other trials while maintaining
randomization. Evaluated endpoints included the incidence of
having1 exacerbation, mortality and study withdrawals. Statis-
tics are reported as odds ratios (ORs) with 95% credible intervals
(CrIs). RESULTS: Fourty-three eligible trials including 31,020
COPD patients were identiﬁed. MTC demonstrated LABA (OR
0.84, 95%CrI, 0.76–0.92), tiotropium (OR 0.69, 95%CrI, 0.61–
0.76), ICS (OR 0.85, 95%CrI, 0.75–0.97), and combination
ICS/LABA (OR 0.76, 95%CrI, 0.67–0.85) therapies each
decreased the odds of having an exacerbation compared to
placebo. Moreover, tiotropium reduced the odds of having an
exacerbation compared to both LABA (OR 0.82, 95%CrI, 0.72–
0.93) or ICS (OR0.81, 95%CrI, 0.69–0.94) therapies. Each of the
4 drug classes were asssociated with signiﬁcantly fewer study
withdrawals compared to placebo with odds reductions ranging
from 26–41%. Additionally, both tiotropium and combination
ICS/LABA therapy signiﬁcantly decreased study withdrawals as
compared to either LABA or ICS therapy alone. The only agent
to demonstrate a mortality beneﬁt was combination LABA/ICS
therapy, which showed superiority to placebo (OR 0.71, 95%CrI,
0.49–0.96) and LABA therapy (OR 0.75, 95%CrI, 0.52–1.00).
CONCLUSION: Combination ICS/LABA therapy appeared to
have the greatest effect on outcomes, including exacerbations and
mortality, while resulting in fewer study withdrawals. Upon com-
paring solo bronchodialator therapies, tiotropium was associated
with a lesser odds of developing an exacerbation or study with-
drawal compared to LABA therapy.
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